SillaJen and Lee’s Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer 2017.07.26

 
 
  Download  


© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD